XNK Therapeutics AB
XNK is a clinical-stage biotechnology company developing individualized natural killer (NK) cell-based cancer therapies. The pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors.
At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed a proprietary technology platform of broad utility and benefits from its tailor-made GMP facility and co-location with the Karolinska Institute and the Karolinska University Hospital. XNK is well positioned to bring transformational autologous NK cell-based therapies and new hope to cancer patients around the world.
Here you can register your spontaneous application or application for a specific job advertisement.